AIM
BTAI icon

Artemis Investment Management’s BioXcel Therapeutics BTAI Stock Holding History

Artemis Investment Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-55,941
Closed -$5.95M – 206
2023
Q2 		$5.95M Sell
55,941
-5,401
-9% -$1.8M 0.07% 162
2023
Q1 		$18.3M Sell
61,342
-22,014
-26% -$9.4M 0.22% 115
2022
Q4 		$28.7M Sell
83,356
-2,550
-3% -$617K 0.33% 89
2022
Q3 		$16.3M Sell
85,906
-653
-0.8% -$152K 0.19% 121
2022
Q2 		$18.3M Sell
86,559
-2,705
-3% -$569K 0.19% 125
2022
Q1 		$29.9M Buy
89,264
+1,115
+1% +$323K 0.24% 111
2021
Q4 		$28.6M Buy
88,149
+1,883
+2% +$808K 0.21% 124
2021
Q3 		$41.9M Buy
86,266
+11,685
+16% +$5.14M 0.33% 89
2021
Q2 		$34.7M Buy
74,581
+10,089
+16% +$5.5M 0.3% 107
2021
Q1 		$44.4M Buy
64,492
+1,151
+2% +$926K 0.42% 72
2020
Q4 		$46.8M Buy
63,341
+734
+1% +$572K 0.49% 64
2020
Q3 		$43.4M Buy
62,607
+18,763
+43% +$14.1M 0.54% 51
2020
Q2 		$37.3M Sell
43,844
-5,341
-11% -$3.48M 0.5% 62
2020
Q1 		$17.4K Sell
49,185
-17,914
-27% -$6.44M 0.03% 92
2019
Q4 		$15.5M Sell
67,099
-7,288
-10% -$733K 0.2% 126
2019
Q3 		$8.37M Buy
74,387
+13,199
+22% +$2.08M 0.11% 184
2019
Q2 		$10.6M Buy
61,188
+627
+1% +$106K 0.13% 188
2019
Q1 		$9.67M Sell
60,561
-12,127
-17% -$1.5M 0.11% 197
2018
Q4 		$4.5M Sell
72,688
-5,740
-7% -$484K 0.06% 218
2018
Q3 		$9.7M Buy
78,428
+1,022
+1% +$152K 0.11% 195
2018
Q2 		$11.4M Buy
77,406
+1,754
+2% +$268K 0.15% 143
2018
Q1 		$12.2M Buy
+75,652
New +$12.6M 0.19% 129

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Artemis Investment Management's BTAI Position: Q3 2023 in Review

Artemis Investment Management sold out of BioXcel Therapeutics (BTAI) in Q3 2023, closing a stake of 55,941 shares — an estimated $5.95M sold.

Artemis Investment Management first reported a position in BTAI in Q1 2018 and held it in 22 quarters. The position peaked at $46.8M in Q4 2020. 85 funds tracked by Wall St. Rank hold BTAI as of Q3 2023.

  • Artemis Investment Management reported no remaining BioXcel Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Artemis Investment Management sold 55,941 BioXcel Therapeutics shares in Q3 2023, an estimated $5.95M.
  • Artemis Investment Management first reported a position in BioXcel Therapeutics in Q1 2018 and held it in 22 quarters.
  • Artemis Investment Management's BioXcel Therapeutics position peaked at $46.8M in Q4 2020.
  • 85 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2023.

Based on Artemis Investment Management's 13F filing for Q3 2023, filed 16 Oct 2023.